Prostate Cancer [2016]: Bulletin #3
Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer.Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating J&J’s Zytiga (abiraterone) plus prednisone, in combination with androgen deprivation therapy (ADT) in patients with hormone-naïve prostate cancer (HNPC); KOL views on the results published in the Cancer Discovery journal which suggest that a blood test measuring circulating free DNA (cfDNA) can be used to assess treatment response in men with advanced prostate cancer who are administered with AstraZeneca's PARP inhibitor Lynparza (olaparib). Finally, the experts provide candid insights into their expectations for Array BioPharma’s and Roche’s Akt inhibitor ipatasertib, which entered Phase III development for patients with metastatic castration-resistant prostate cancer (mCRPC) in May 2017.
Business Questions:
Business Questions:
- What are the experts’ opinions on the results of the Phase III LATITUDE and STAMPEDE studies?
- Do the KOLs anticipate any change in the treatment of HNPC patients based on the results of the LATITUDE and STAMPEDE studies?
- How will the results of the LATITUDE and STAMPEDE studies impact prescribing of Astellas/Pfizer’s Xtandi (enzalutamide)?
- Which findings in the cfDNA study published in the journal Cancer Discovery do KOLs perceive to be the most important?
- Do KOLs anticipate using cfDNA to measure treatment response in olaparib-treated patients?
- What are KOL expectations for olaparib in metastatic CRPC?
- How do KOLs view the future potential for treating metastatic CRPC?
- How does Array BioPharma/Roche’s ipatasertib target patient population compare to that of AstraZeneca’s olaparib?
- What do the experts think about the strategy of selecting patients with PTEN loss in the Phase III study with ipatasertib?
